We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+16.95%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$1.52B
AUM Growth
-$7.28B
Cap. Flow
-$6.76B
Cap. Flow %
-444.29%
Top 10 Hldgs %
100%
Holding
929
New
Increased
6
Reduced
3
Closed
920

Sector Composition

Rank Sector Weight
1 Technology 45.54%
2 Healthcare 36.97%
3 Financials 14.43%
4 Communication Services 3.06%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASBP
376
Aspire Biopharma
ASBP
$10.1M
-191
Closed -$2.33M
XAGE
377
DELISTED
Longevity Health Holdings, Inc. Common Stock
XAGE
-49,500
Closed -$14.5M
AMPS
378
DELISTED
Altus Power
AMPS
-207,098
Closed -$2.28M
SKGRU
379
DELISTED
SK Growth Opportunities Corporation Unit
SKGRU
-919,138
Closed -$9.23M
GATE
380
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
-476,606
Closed -$4.75M
PLAO
381
DELISTED
Patria Latin American Opportunity Acquisition Corp. Class A Ordinary Shares
PLAO
-367,656
Closed -$3.74M
PNST
382
DELISTED
Pinstripes Holdings, Inc.
PNST
-233,953
Closed -$2.34M
NKGN
383
DELISTED
NKGen Biotech, Inc. Common Stock
NKGN
-320,103
Closed -$3.12M
ROIC
384
DELISTED
Retail Opportunity Investments Corp.
ROIC
-200,612
Closed -$2.76M
ALCE
385
DELISTED
Alternus Clean Energy Inc
ALCE
-9,191
Closed -$2.27M
RVNC
386
DELISTED
Revance Therapeutics, Inc.
RVNC
-101,179
Closed -$2.73M
RVNC
387
PUT
DELISTED
Revance Therapeutics, Inc.
RVNC
-100,000
Closed -$48K
PLMJ
388
DELISTED
Plum Acquisition Corp. III Class A Ordinary Shares
PLMJ
-381,797
Closed -$3.75M
CITE
389
DELISTED
Cartica Acquisition Corp Class A Ordinary Shares
CITE
-210,558
Closed -$2.13M
CSLM
390
DELISTED
CSLM Acquisition Corp. Class A Ordinary Share
CSLM
-233,953
Closed -$2.32M
CFFS
391
DELISTED
CF Acquisition Corp. VII Class A Common Stock
CFFS
-374,325
Closed -$3.75M
IVCB
392
DELISTED
Investcorp Europe Acquisition Corp I Class A Ordinary Shares
IVCB
-233,953
Closed -$2.37M
MITA
393
DELISTED
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
-238,623
Closed -$2.34M
PRLH
394
DELISTED
Pearl Holdings Acquisition Corp Class A Ordinary Shares
PRLH
-233,953
Closed -$2.35M
BFAC
395
DELISTED
Battery Future Acquisition Corp.
BFAC
-233,953
Closed -$2.36M
BOCN
396
DELISTED
Blue Ocean Acquisition Corp Class A Ordinary Shares
BOCN
-561,488
Closed -$5.63M
APXI
397
DELISTED
APx Acquisition Corp. I Class A Ordinary Share
APXI
-280,744
Closed -$2.85M
CTLT
398
DELISTED
CATALENT, INC.
CTLT
-7,800
Closed -$564K
EVE
399
DELISTED
EVe Mobility Acquisition Corp
EVE
-233,953
Closed -$2.36M
GHIX
400
DELISTED
Gores Holdings IX, Inc. Class A Common Stock
GHIX
-2,339,534
Closed -$22.6M

Similar funds

UBS O'Connor's Q4 2022 Portfolio in Review

As of Q4 2022, UBS O'Connor held 929 positions worth $1.52B, down 83% from $8.8B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

UBS O'Connor withdrew a net $6.76B in Q4 2022, closing 920 positions and reducing 3 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.

Against the trend, UBS O'Connor added an estimated $184M to Horizon Therapeutics Public Limited Company Ordinary Shares.

  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
  • UBS O'Connor's biggest Q4 2022 reduction was Activision Blizzard, cutting an estimated $45.3M.
  • UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
  • UBS O'Connor's ten largest holdings make up 100% of its $1.52B portfolio in Q4 2022.
  • UBS O'Connor opened 0 new positions and closed 920 in Q4 2022.
  • UBS O'Connor's portfolio value fell 83% quarter-over-quarter to $1.52B.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.